In a patient with acute coronary syndrome and an elevated pro‑BNP but no signs of heart failure or acute congestion, should a sodium‑glucose cotransporter‑2 (SGLT‑2) inhibitor be initiated?

SGLT2 Inhibitors in ACS with Elevated Pro-BNP Without Heart Failure

Yes, initiate an SGLT2 inhibitor in this patient, ideally before hospital discharge. The 2023 ACC/AHA guidelines support SGLT2 inhibitor use in chronic coronary disease (which includes post-ACS patients) with heart failure regardless of ejection fraction, and emerging evidence demonstrates safety and mortality benefit when initiated early after acute coronary syndrome 1.

Guideline-Based Rationale

The most recent 2023 ACC/AHA Chronic Coronary Disease guidelines provide clear direction 1:

• Class 1 recommendation (strongest): SGLT2 inhibitors are recommended in patients with chronic coronary disease and heart failure with LVEF ≤40% to reduce cardiovascular death and heart failure hospitalization, irrespective of diabetes status
• Class 2a recommendation: SGLT2 inhibitors can be beneficial in patients with chronic coronary disease and heart failure with LVEF >40% to decrease heart failure hospitalizations and improve quality of life, irrespective of diabetes status
• Class 1 recommendation: In patients with chronic coronary disease and type 2 diabetes, SGLT2 inhibitors are recommended to reduce major adverse cardiovascular events

Interpreting Elevated Pro-BNP in Your Patient

An elevated pro-BNP in the setting of ACS, even without overt clinical heart failure, signals subclinical cardiac dysfunction and elevated risk. This biomarker elevation meets the threshold for "heart failure" as defined in contemporary guidelines—you don't need pulmonary edema or rales to justify SGLT2 inhibitor therapy. The patient likely has:

• Subclinical left ventricular dysfunction
• Elevated filling pressures
• High risk for future heart failure hospitalization
• Indication for cardioprotective therapy

Timing: Why Initiate During Hospitalization

The hospitalization for ACS is the optimal window to start SGLT2 inhibitors, not a reason to defer. Multiple lines of evidence support early initiation 2, 3:

• SGLT2 inhibitors initiated within 24 hours of ACS admission were independently associated with lower in-hospital mortality (OR 0.27,95% CI: 0.07-0.96) 3
• Clinical benefits accrue rapidly within days to weeks 2
• Deferring to outpatient setting results in >75% of eligible patients never receiving the medication within the next year 2
• The SOLOIST-WHF trial demonstrated safety and efficacy when initiated pre-discharge or early post-discharge 2

Safety Profile in Acute Setting

SGLT2 inhibitors have a favorable safety profile that makes them well-suited for acute initiation 2, 4:

• Minimal to no blood pressure effects (unlike ACE inhibitors or beta-blockers)
• No excess risk of adverse kidney events
• Initial eGFR dip of 3-5 mL/min/1.73 m² is expected and reversible—not a reason to discontinue 5
• Safe in hemodynamically stable patients
• Can be initiated even with mild residual congestion once IV therapies are stopped 6

Clinical Evidence in ACS Populations

Recent meta-analyses demonstrate consistent benefits when SGLT2 inhibitors are used in ACS 7, 8, 9:

• Reduction in all-cause mortality (HR 0.77,95% CI: 0.67-0.89) 7
• Reduction in cardiovascular mortality (HR 0.83,95% CI: 0.70-0.99) 7
• Reduction in major adverse cardiovascular events (OR 0.44,95% CI: 0.30-0.64) 8
• Reduction in heart failure hospitalization (RR 0.78,95% CI: 0.66-0.92) 9
• Improved cardiac remodeling with reduced LV dimensions and improved ejection fraction 8, 10

Practical Implementation Algorithm

Follow this sequence for SGLT2 inhibitor initiation in your patient:

1. Confirm eligibility:

   • eGFR ≥20 mL/min/1.73 m² (can initiate; continue until dialysis if needed) 5
   • Hemodynamically stable (no ongoing shock, stable blood pressure)
   • Off IV inotropes/vasopressors or on minimal stable doses

2. Choose agent with proven cardiovascular benefit:

   • Empagliflozin, dapagliflozin, or canagliflozin 1
   • Start at standard dose (no need for low-dose initiation)

3. Timing within hospitalization:

   • Initiate once acute phase stabilized (typically 24-48 hours post-revascularization)
   • Can start even with mild residual congestion
   • Ideally before discharge to ensure adherence

4. Monitor:

   • Recheck creatinine in 1-2 weeks (expect small reversible dip)
   • Educate on genital hygiene to prevent mycotic infections
   • Provide "sick day rules" (hold during acute illness with vomiting/diarrhea)

Common Pitfalls to Avoid

Do not defer initiation based on:

• Absence of clinical heart failure symptoms (elevated BNP is sufficient)
• Normal ejection fraction (benefits extend to HFpEF)
• Mild renal dysfunction (safe down to eGFR 20)
• "Waiting to see how they do outpatient" (most won't get started)

Do not discontinue for:

• Expected small eGFR dip in first 4 weeks
• Absence of diabetes (benefits are independent of diabetes status) 1

Integration with Other Guideline-Directed Therapies

Your patient should receive the full post-ACS regimen 1, 11:

• Antiplatelet therapy: Aspirin + P2Y12 inhibitor (ticagrelor or prasugrel preferred) for 12 months
• High-intensity statin: Started immediately
• Beta-blocker: For 3 years minimum (Class 1 if LVEF ≤40%)
• ACE inhibitor/ARB: Especially if LVEF ≤40%, hypertension, or diabetes
• SGLT2 inhibitor: As discussed above
• Consider MRA: If LVEF ≤35% with heart failure or diabetes

The SGLT2 inhibitor complements rather than replaces these therapies and can be initiated in parallel with beta-blockers and ACE inhibitors during the same hospitalization 6.